207 related articles for article (PubMed ID: 31899122)
1. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Randrian V; Adenis A; Desrame J; Barbier E; Di Fiore F; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Breysacher G; Roquin G; Louafi S; Lopez A; Louvet C; Borg C; Metges JP; Faroux R; Gaba L; Manfredi S; Tougeron D
Dig Liver Dis; 2020 Mar; 52(3):347-350. PubMed ID: 31899122
[TBL] [Abstract][Full Text] [Related]
2. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
Craig Z; Swain J; Batman E; Wadsley J; Reed N; Faluyi O; Cave J; Sharma R; Chau I; Wall L; Lamarca A; Hubner R; Mansoor W; Sarker D; Meyer T; Cairns DA; Howard H; Valle JW; McNamara MG
BMJ Open; 2020 Feb; 10(2):e034527. PubMed ID: 32029495
[TBL] [Abstract][Full Text] [Related]
3. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
5. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.
Yamamoto S; Kawakami H; Kii T; Hara H; Kawabata R; Kawada J; Takeno A; Matsuyama J; Ueda S; Okita Y; Endo S; Kimura Y; Yanagihara K; Okuno T; Kurokawa Y; Shimokawa T; Satoh T
Eur J Cancer; 2021 Sep; 154():307-315. PubMed ID: 34311300
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
9. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
[TBL] [Abstract][Full Text] [Related]
11. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
14. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
[TBL] [Abstract][Full Text] [Related]
16. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Huang TC; Lin CC; Wu YC; Chia-Hsien Cheng J; Lee JM; Wang HP; Huang PM; Hsu FM; Yeh KH; Cheng AL; Tzen KY; Hsu CH
J Formos Med Assoc; 2019 Jun; 118(6):1024-1030. PubMed ID: 30502100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]